Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The appearnce of Recurring Royalties

included in PTSC's filings, and even vocally expressed at the SHM. Even if they "never" signed such licenses, that statement is only providing notice that they "may" at some point.

"PDS may at times enter into license agreements whereby contingent revenues are recognized as one or more contractual milestones"

When asked directly by an Investor some year or two ago, PTSC responded that as of yet, there were no recurring royalty licenses signed.

Share
New Message
Please login to post a reply